Primary surgery versus no surgery in synchronous metastatic breast cancer: patient-reported quality-of-life outcomes of the prospective randomized multicenter ABCSG-28 Posytive Trial.

Bjelic-Radisic, V; Fitzal, F; Knauer, M; Steger, G; Egle, D; Greil, R; Schrenk, P; Balic, M; Singer, C; Exner, R; Soelkner, L; Gnant, M; BMC Cancer. 2020; 20(1):392

Safe application of extensive radiotherapy to a cardiac resynchronization device.

Schernthaner, C; Kopp, M; Dagn, K; Rettenbacher, L; Weiss, L; Meyersburg, D; Brandt, MC; Hoppe, UC; Strohmer, B; ESC Heart Fail. 2020; 7(6):4293-4296

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options.

Gampenrieder, SP; Castagnaviz, V; Rinnerthaler, G; Greil, R CANCER MANAG RES. 2020; 12: 10615-10629.

Interdisciplinary Model for Scheduling Post-discharge Cardiopulmonary Care of Patients Following Severe and Critical SARS-CoV-2 (Coronavirus) Infection.

Kopp, K; Lichtenauer, M; Motloch, LJ; Hoppe, UC; Egle, A; Salzer, HJF; Lamprecht, B; Tomasits, J; Müller, HM; Dieplinger, A; Front Cardiovasc Med. 2020; 7:157

Health-Related Quality of Life in Patients With Hodgkin Lymphoma: A Longitudinal Analysis of the German Hodgkin Study Group.

Kreissl, S; Muller, H; Goergen, H; Meissner, J; Topp, M; Sokler, M; Markova, J; Bernhard, J; Greil, R; von Tresckow, B; Behringer, K; Ruffer, JU; Flechtner, HH; Mostl, M; Fuchs, M; Engert, A; Diehl, V; Borchmann, P J CLIN ONCOL. 2020; 38(25): 2839-2848.

Dabrafenib plus trametinib in patients with BRAF

Subbiah, V; Lassen, U; EElez, E; Italiano, A; Curigliano, G; Javle, M; de Braud, F; Prager, GW; Greil, R; Stein, A; Fasolo, A; Schellens, JHM; Wen, PY; Viele, K; Boran, AD; Gasal, E; Burgess, P; Ilankumaran, P; Wainberg, ZA LANCET ONCOL. 2020; 21(9): 1234-1243.

Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.

Sestak, I; Filipits, M; Buus, R; Rudas, M; Balic, M; Knauer, M; Kronenwett, R; Fitzal, F; Cuzick, J; Gnant, M; Greil, R; Dowsett, M; Dubsky, P CLIN CANCER RES. 2020; 26(17): 4682-4687.

The Effect of

Leeksma, AC; Derks, IAM; Kasem, MH; Kilic, E; de Klein, A; Jager, MJ; van de Loosdrecht, AA; Jansen, JH; Navrkalova, V; Faber, LM; Zaborsky, N; Egle, A; Zenz, T; Pospisilova, S; Abdel-Wahab, O; Kater, AP; Eldering, E FRONT ONCOL. 2020; 10: 609409

IDO in MDS/AML disease progression and its role in resistance to azacitidine: a potential new drug target?

Leisch, M; Greil, R; Pleyer, L BRIT J HAEMATOL. 2020; 190(3): 314-317.

A phase 1 study to evaluate the feasibility and efficacy of the addition of ropeginterferon alpha-2b to imatinib treatment in patients with chronic phase chronic myeloid leukemia (CML) not achieving a deep molecular response (molecular remission 4.5)-AGMT_CML 1.

Heibl, S; Buxhofer-Ausch, V; Schmidt, S; Webersinke, G; Lion, T; Piringer, G; Kuehr, T; Wolf, D; Melchardt, T; Greil, R; Thaler, J HEMATOL ONCOL. 2020; 38(5): 792-798.